A study conducted by Gradinaru et al. [54] to investigate the connections between adiponectin and cardiovascular risk factors in elderly patients with metabolic syndrome demonstrated significant positive correlations between adiponectin and high-density lipoprotein (HDL) (p < 0.05), the total cholesterol/low-density lipoproteins (LDL) ratio (p < 0.01), and improved endothelial function. Here, ADIPOQ is linked to metabolic syndrome.